teaser
Roche has announced plans for a major restructuring of its R&D activities around five therapeutic areas which, it says, should speed up development of drugs and increase efficiency.
The plan involves setting up disease biology areas (DBAs), which will cover the whole range of activities from R&D to strategic marketing in a specific therapeutic field and be located at one site. The five DBAs are oncology (based in Nutley, NJ, USA), virology and inflammation (at Palo Alto, CA, USA), metabolism and central nervous system (Basel, Switzerland).
